82 related articles for article (PubMed ID: 7602375)
1. Dose-intensive treatment of acute myelogenous leukemia: improved survival?
Schiller G
J Clin Oncol; 1995 Jul; 13(7):1828-30. PubMed ID: 7602375
[No Abstract] [Full Text] [Related]
2. Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?
Berman E
J Clin Oncol; 1995 Jan; 13(1):1-4. PubMed ID: 7799008
[No Abstract] [Full Text] [Related]
3. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
[TBL] [Abstract][Full Text] [Related]
4. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
6. Progress in acute myelogenous leukemia.
Gale RP
Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
[TBL] [Abstract][Full Text] [Related]
7. Questions regarding frontline therapy of acute myeloid leukemia.
Kantarjian H; O'Brien S
Cancer; 2010 Nov; 116(21):4896-901. PubMed ID: 20623787
[No Abstract] [Full Text] [Related]
8. [Short-term intensive consolidation chemotherapy in the treatment of acute non-lymphocytic leukemia].
Nagata K; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1079-81. PubMed ID: 1626944
[No Abstract] [Full Text] [Related]
9. Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P; Gattringer C; Petti MC; Solbu G
Leukemia; 1992; 6 Suppl 2():114-5. PubMed ID: 1578909
[No Abstract] [Full Text] [Related]
10. Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
Stein RS; Flexner JM
Cancer Treat Rep; 1979; 63(11-12):2123-4. PubMed ID: 294309
[No Abstract] [Full Text] [Related]
11. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
12. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
[No Abstract] [Full Text] [Related]
13. Improved survival for patients with acute myelogenous leukemia.
Mitus AJ; Miller KB; Schenkein DP; Ryan HF; Parsons SK; Wheeler C; Antin JH
J Clin Oncol; 1995 Mar; 13(3):560-9. PubMed ID: 7884416
[TBL] [Abstract][Full Text] [Related]
14. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
Bär BM; de Witte T; de Pauw BE; Haanen C
Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
[TBL] [Abstract][Full Text] [Related]
15. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
[TBL] [Abstract][Full Text] [Related]
16. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
17. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
[TBL] [Abstract][Full Text] [Related]
18. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
19. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
20. Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
Zittoun R; Marie JP; Brilhante D; Delmer A
Haematol Blood Transfus; 1987; 30():45-9. PubMed ID: 3476378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
